Evaluation of AMG 420, an anti-BCMA bispecific T-cell engager (BiTE) immunotherapy, in R/R multiple myeloma (MM) patients: Updated results of a first-in-human (FIH) phase I dose escalation study.

Max S. Topp,Johannes Duell,Gerhard Zugmaier,Michel Attal,Philippe Moreau,Christian Langer,Jan Kroenke,Thierry Facon,Alexey Salnikov,Robin Lesley,Karl Beutner,James Kalabus,Erik Rasmussen,Kathrin Riemann,Alex C. Minella,Gerd Munzert,Hermann Einsele

Evaluation of AMG 420, an anti-BCMA bispecific T-cell engager (BiTE) immunotherapy, in R/R multiple myeloma (MM) patients: Updated results of a first-in-human (FIH) phase I dose escalation study.

2019

Max S. Topp
Johannes Duell
Gerhard Zugmaier
Michel Attal
Philippe Moreau
Christian Langer
Jan Kroenke
Thierry Facon
Alexey Salnikov
Robin Lesley
Karl Beutner
James Kalabus
Erik Rasmussen
Kathrin Riemann
Alex C. Minella
Gerd Munzert
Hermann Einsele

8007Background: Objectives of this study included assessing safety and activity of AMG 420/BI 836909, which binds BCMA (B-Cell Maturation Antigen) on MM cells and CD3 on T cells, in relapsed and/or...

Keywords:

Pathology
Cancer research
Antigen
Immunotherapy
T cell
Medicine
CD3
Multiple myeloma
first in human
dose escalation

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations